2023
1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Lemelin A, Takemura K, Boyne D, Warkentin M, Brenner D, Cheun W, Wells J, Labaki C, McGregor B, Basappa N, Meza L, Pal S, Beuselinck B, McKay R, Szabados B, Powles T, Yuasa T, Ludwig L, Choueiri T, Heng D. 1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC). Annals Of Oncology 2023, 34: s1023-s1024. DOI: 10.1016/j.annonc.2023.09.1132.Peer-Reviewed Original Research
2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Graham J, Wells J, Dudani S, Gan C, Donskov F, Lee J, Kollmannsberger C, Meza L, Beuselinck B, Hansen A, North S, Bjarnason G, Sayegh N, Kanesvaran R, Wood L, Hotte S, McKay R, Choueiri T, Heng D. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal Of Cancer 2022, 171: 124-132. PMID: 35717820, DOI: 10.1016/j.ejca.2022.05.002.Peer-Reviewed Original ResearchConceptsInternational Metastatic RCC Database ConsortiumImmune checkpoint inhibitor groupImmune checkpoint inhibitorsVascular endothelial growth factorICI-based therapyObjective response rateVascular endothelial growth factor groupMammalian target of rapamycinClear-cell renal cell carcinomaFirst-line therapyOutcomes of patientsRenal cell carcinomaTreatment failureOverall survivalInhibitor monotherapyCell carcinomaFirst-lineAdvanced non-clear cell renal cell carcinomaInternational Metastatic RCC Database Consortium risk groupMammalian target of rapamycin-targeted therapiesMetastatic clear-cell renal cell carcinomaNon-clear cell renal cell carcinomaNon-clear cell RCCAssociated with improved OSMedian TTFCharacterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
Ernst M, Navani V, Wells J, Donskov F, Basappa N, Labaki C, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Parnis F, Suárez C, Yuasa T, Kapoor A, Alva A, Bjarnason G, Choueiri T, Heng D. Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 308-308. DOI: 10.1200/jco.2022.40.6_suppl.308.Peer-Reviewed Original ResearchInternational mRCC Database ConsortiumMetastatic renal cell carcinomaVascular endothelial growth factor-targeted therapyIpi-nivoImmuno-oncology agentsOverall survivalCombination therapyComplete responseFirst-lineFirst-line treatment of metastatic renal cell carcinomaTreatment of metastatic renal cell carcinomaInternational mRCC Database Consortium criteriaClinical trialsFirst-line combination therapyEfficacy of combination therapyNon-clear cell histologyTherapy to deathFirst-line treatmentLog-rank testRenal cell carcinomaReal-world survivalCell histologySarcomatoid featuresOS outcomesLiver metastasesPredictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).
Navani V, Ernst M, Wells C, Yuasa T, Takemura K, Donskov F, Basappa N, Schmidt A, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Weickhardt A, Suárez C, Kapoor A, Lee J, Choueiri T, Heng D. Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 310-310. DOI: 10.1200/jco.2022.40.6_suppl.310.Peer-Reviewed Original ResearchAssociated with responseCytoreductive nephrectomyIpi-nivoLung metastasesMetastatic renal cell carcinomaPresence of lung metastasesResponse to first-lineImmunotherapy combination regimensMedian overall survivalRenal cell carcinomaPredictors of responseEndothelial growth factorIpilimumab-nivolumabSarcomatoid histologyRECIST v1.1Combination regimensOverall survivalCombination therapyCell carcinomaFirst-lineResponse of CRNon-respondersPrognostic riskClinical variablesPatient counseling
2021
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Gan C, Wells J, Schmidt A, Powles T, Tran B, Meza L, Labaki C, Lee J, Wood L, Shapiro J, Ernst D, Kapoor A, Canil C, Yuasa T, McKay R, Beuselinck B, Donskov F, Dudani S, Choueiri T, Heng D. Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal Of Clinical Oncology 2021, 39: 4554-4554. DOI: 10.1200/jco.2021.39.15_suppl.4554.Peer-Reviewed Original ResearchInternational mRCC Database ConsortiumMetastatic renal cell carcinomaIpi-nivoOverall survivalCell histologyInternational mRCC Database Consortium criteriaOutcomes of first-lineTreatment durationNon-clear cell histologyPoor-risk diseaseTyrosine kinase inhibitorsRenal cell carcinomaRisk categoriesMedian OSBrain metastasesBone metastasesLiver metastasesPoor riskRisk diseaseCell carcinomaFirst-lineMedian ageProgressive diseaseMedian TDNeutrophil count